Measurement of collagen-and serotonin-induced platelet aggregation in whole blood

Expert Review of Clinical Pharmacology

Volumn 3, Issue 2, 2010, Pages 177-182

  Moerland, Matthijs ^a   Kemme, Michiel J ^a   Van Der Linden, Monique ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Collagen; Impedance aggregometry; Platelet aggregation; Serotonin; Whole blood

Indexed keywords

ANTITHROMBOCYTIC AGENT; COLLAGEN; KETANSERIN; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST;

ANALYTIC METHOD; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; CORRELATION COEFFICIENT; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; HEART MUSCLE ISCHEMIA; HUMAN; IMPEDANCE AGGREGOMETRY; NONHUMAN; PROTEIN INDUCTION; RELIABILITY; REPRODUCIBILITY; REVIEW; SEROTONIN BLOOD LEVEL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

EID: 77949393644     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.2     Document Type: Review

References (37)

1. Corti R, Badimon JJ. Biologic aspects of vulnerable plaque. Curr. Opin. Cardiol. 17, 616-625 (2002).
2. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J. Thromb. Haemost. 2, 561-573 (2004).
3. Leysen JE, de Chaffoy DC, de Clerck F, Niemegeers CJ, Van Nueten JM. Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology 23, 1493-1501 (1984).
4. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther. 68, 435-442 (2000).
5. Belcher PR, Drake-Holland AJ, Noble MI. The antiplatelet drug target in atherosclerotic diseases. Cardiovasc. Hematol. Disord. Drug Targets 6, 43-55 (2006).
6. 2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 104, 59-81 (2004).
7. Noble MI, Drake-Holland AJ. Evidence for a role of serotonin in initiation of coronary arterial thrombosis in dog and man. Clin. Physiol. Biochem. 8(Suppl. 3), 50-55 (1990).
8. 2 receptor antagonism in cardioprotection. Neth. J. Med. 41, 183-189 (1992).
9. 2 receptor antagonist ritanserin. Cardiovasc. Res. 24, 465-470 (1990).
10. Ozdener F, Gulbas Z, Erol K, Ozdemir V. 5-Hydroxytryptamine-2A receptor gene (HTR2A) candidate polymorphism (T 102 C): role for human platelet function under pharmacological challenge ex vivo. Methods Find. Exp. Clin. Pharmacol. 27, 395-400 (2005).
11. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation 100, 483-489 (1999).
12. Yamada S, Akita H, Kanazawa K et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 150, 143-148 (2000).
13. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus. Apher. Sci. 28, 307-317 (2003).
14. Ingerman-Wojenski C. Simultaneous measurement of platelet aggregation and the release reaction in platelet-rich plasma and in whole blood. J. Med. Technol. 1, 697-701 (1984).
15. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin. Appl. Thromb. Hemost. 11, 25-35 (2005).
16. Lumley P, Humphrey PP. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J. Pharmacol. Methods 6, 153-166 (1981).
17. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Methods 3, 135-158 (1980).
18. Riess H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am. J. Clin. Pathol. 85, 50-56 (1986).
19. Willoughby SR, Chirkova LP, Horowitz JD, Chirkov YY. Multiple agonist induction of aggregation: an approach to examine anti-aggregating effects in vitro. Platelets 7, 329-333 (1996).
20. Menys VC. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro. Cardiovasc. Res. 27, 1916-1919 (1993).
21. Qi R, Yatomi Y, Ozaki Y. Effects of incubation time, temperature, and anticoagulants on platelet aggregation in whole blood. Thromb. Res. 101, 139-144 (2001).
22. 2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle. Br. J. Pharmacol. 121, 875-882 (1997).
23. Arneklo-Nobin B, Elmer O, Akesson A. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study. Int. Angiol. 7, 19-25 (1988).
24. Yao JK, van Kammen DP, Moss HB, Sokulski DE. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res. 63, 123-132 (1996).
25. Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vermylen J. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients. J. Cardiovasc. Pharmacol. 6, 182-185 (1984).
26. 2-receptor antagonist. Agents Actions 12, 388-397 (1982).
27. 2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro. Agents Actions 17, 515-526 (1986).
28. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb. Haemost. 96, 781-788 (2006).
29. O'Donnell CJ, Larson MG, Feng D et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation 103, 3051-3056 (2001).
30. Lee K W, Lip GY. Effects of lifestyle on hemostasis, fbrinolysis, and platelet reactivity: a systematic review. Arch. Intern. Med. 163, 2368-2392 (2003).
31. Brogden RN, Sorkin EM. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs 40, 903-949 (1990).
32. Martin GR, Humphrey PP. Receptors for 5-hydroxytryptamine: current perspectives on classifcation and nomenclature. Neuropharmacology 33, 261-273 (1994).
33. 2A receptors: implications for psychiatric research. Psychiatry Res. 80, 227-238 (1998).
34. 2 receptor sites on human blood platelets. Biochem. Pharmacol. 33, 2807-2811 (1984).
35. 2 serotonergic receptors. J. Pharmacol. Exp. Ther. 218, 217-230 (1981).
36. Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch. Pharmacol. 376, 45-63 (2007).
37. Malinin AI, Ong S, Makarov LM, Petukhova EY, Serebruany VL. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int. J. Clin. Pract. 60, 993-1002 (2006).